Citadel Advisors
VTGN icon

Citadel Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Citadel Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-122,062
Closed -$441K – 14207
2025
Q3 		$433K Buy
+122,062
New +$365K ﹤0.01% 9482
2024
Q4 		– Sell
-321,885
Closed -$906K – 15471
2024
Q3 		$969K Sell
321,885
-307,760
-49% -$1.05M ﹤0.01% 6925
2024
Q2 		$2.19M Sell
629,645
-114,275
-15% -$495K ﹤0.01% 5142
2024
Q1 		$3.93M Buy
743,920
+425
+0.1% +$2.04K ﹤0.01% 4329
2023
Q4 		$3.82M Buy
743,495
+734,943
+8,594% +$2.78M ﹤0.01% 4210
2023
Q3 		$44.8K Sell
8,552
-11,319
-57% -$50.3K ﹤0.01% 11875
2023
Q2 		$37.2K Buy
19,871
+19,282
+3,274% +$67.6K ﹤0.01% 12130
2023
Q1 		$2.2K Sell
589
-7,061
-92% -$37K ﹤0.01% 14184
2022
Q4 		$23.6K Buy
7,650
+4,227
+123% +$15.9K ﹤0.01% 13005
2022
Q3 		$16K Sell
3,423
-39,610
-92% -$393K ﹤0.01% 12152
2022
Q2 		$1.14M Buy
43,033
+8,206
+24% +$290K ﹤0.01% 6737
2022
Q1 		$1.3M Buy
34,827
+30,294
+668% +$1.32M ﹤0.01% 7098
2021
Q4 		$266K Buy
4,533
+329
+8% +$21.4K ﹤0.01% 11189
2021
Q3 		$346K Buy
4,204
+3,805
+954% +$331K ﹤0.01% 10745
2021
Q2 		$38K Sell
399
-3,208
-89% -$238K ﹤0.01% 13432
2021
Q1 		$230K Buy
+3,607
New +$241K ﹤0.01% 11433
2018
Q3 		– Sell
-506
Closed -$21K – 9730
2018
Q2 		$21K Buy
+506
New +$17.6K ﹤0.01% 8644
2017
Q4 		– Sell
-446
Closed -$21K – 8488
2017
Q3 		$21K Buy
+446
New +$23.5K ﹤0.01% 7351

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's VTGN Position: Q4 2025 in Review

Citadel Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 122,062 shares — an estimated $441K sold.

Citadel Advisors first reported a position in VTGN in Q3 2017 and held it in 18 quarters. The position peaked at $3.93M in Q1 2024. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Citadel Advisors reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 122,062 VistaGen Therapeutics shares in Q4 2025, an estimated $441K.
  • Citadel Advisors first reported a position in VistaGen Therapeutics in Q3 2017 and held it in 18 quarters.
  • Citadel Advisors's VistaGen Therapeutics position peaked at $3.93M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.